Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | LDHB | P07195 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19660004 | 0.86 | PTPN1 (0.50) | PTPN1GSK3BPDPK1ALDH1A1MAPT | |
| SCHEMBL19660200 | 0.82 | HDAC3 (0.48) | ALDH1A1KMT2AHDAC1HDAC8MMP2 | |
| SCHEMBL19642328 | 0.82 | PDPK1 (0.65) | PTPN1GSK3BPDPK1ALDH1A1MAPT | |
| SCHEMBL19659999 | 0.80 | L3MBTL1 (0.60) | GSK3BALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL19660150 | 0.79 | L3MBTL1 (0.50) | GSK3BALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL19660210 | 0.79 | KMT2A (0.49) | GSK3BALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL22281426 | 0.79 | GSK3B (0.61) | GSK3BALDH1A1MAPTMMP1KMT2A | |
| SCHEMBL22281608 | 0.79 | L3MBTL1 (0.64) | GSK3BALDH1A1KMT2AL3MBTL1HTT | |
| SCHEMBL20714549 | 0.79 | TAS1R3 (0.44) | KMT2AHDAC8L3MBTL1 | |
| SCHEMBL20714737 | 0.79 | NOTUM (0.49) | ALDH1A1MAPTKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-05 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| CN-116554152-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116531380-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-110678459-B | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-109863140-B | 3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamide | 拜耳医药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11459312-B2 | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-04 | — | — | US | disclosed |
| EP-3464248-B1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-22 | — | — | US | disclosed |
| EP-3580211-B1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AG (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-20200299269-A1 | SULPHUR SUBSTITUTED 3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| CN-110678459-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2020-01-10 | — | — | CN | disclosed |
| WO-2017202816-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459312-B2 | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | AHR, ARNT, MYD88 | PTPN1 1281/4885GSK3B 3265/4885PDPK1 2507/4885 |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, CBR1, CNR1 | PTPN1 1040/4885GSK3B 2364/4885PDPK1 2079/4885 |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | AHR, HRH2, HRH4 | PTPN1 2253/4885GSK3B 2955/4885PDPK1 1443/4885 |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | AHR, ARNT, HRH2 | PTPN1 2002/4885GSK3B 2339/4885PDPK1 1505/4885 |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, ARNT, HRH2 | PTPN1 2002/4885GSK3B 2339/4885PDPK1 1505/4885 |
| US-20200299269-A1 | SULPHUR SUBSTITUTED 3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | AHR, HRH2, ARNT | PTPN1 1219/4885GSK3B 2948/4885PDPK1 2609/4885 |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | AHR, HRH2, HRH4 | PTPN1 2253/4885GSK3B 2955/4885PDPK1 1443/4885 |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, ARNT, HRH2 | PTPN1 2161/4885GSK3B 2301/4885PDPK1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.